Molecular profile
Molecular profile
- Molecule class
- Synthetic peptide
- Origin
- Endogenous fragment
- Primary target system
- Entzündungs- und Barriereprozesse; melanocortinunabhängige Mechanismen werden diskutiert
- Development stage
- Preclinical development
C-terminales Tripeptidfragment von alpha-MSH.
Mechanism and signalling
Mechanism and signalling
Reported effects involve pro-inflammatory signalling and microbial interactions. Some observed activity may not be fully explained by classical melanocortin receptors.
Scientific classification
Scientific classification
This profile maps KPV to the research areas immune, gastrointestinal, dermatology. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.
Innate immunity, epithelial barriers and antimicrobial peptide functions.
Peptide-based regulation of secretion, motility and the intestinal barrier.
Skin matrix, pigmentation biology, copper peptides and melanocortin signalling.
Evidence base
Preclinical
The evidence is predominantly preclinical. Controlled human trials, standardised formulations and robust long-term safety data are lacking.
Regulatory status
Not generally authorised
This research substance has no general medicinal authorisation in Germany or the EU. Labels such as “research peptide” do not replace regulatory approval.
Safety and use notice
No dosing or administration recommendation
The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.
Sources and registries